Aditxt Progresses with Appili Therapeutics Acquisition Pending Funding

Aditxt Inc. (NASDAQ: ADTX), through its subsidiary Adivir, Inc., is advancing its acquisition plans of Appili Therapeutics under a court-approved plan of arrangement. Appili shareholders have approved the transaction, with all necessary court sanctions secured; however, the completion of the deal is contingent on Aditxt obtaining sufficient financing before March 31, 2025. As part of the agreement, Aditxt paid $250,000 for an extension. Additionally, Appili seeks up to $117.5 million in U.S. federal funding to aid in developing infectious disease therapies, enhancing its profile in the biopharmaceutical arena. Aditxt's overarching strategy involves implementing multiple autonomous programs tackling prevalent societal health challenges, supported by its network of research institutions, partners, and stakeholders. The completion of acquisitions, including Appili and Evofem, depends on further approvals and financing, with no guarantees of closure at this stage.